Crossref journal-article
American Association for the Advancement of Science (AAAS)
Science (221)
Abstract

A new class of protein tyrosine kinase inhibitors was identified that is based on an oxindole core (indolinones). Two compounds from this class inhibited the kinase activity of fibroblast growth factor receptor 1 (FGFR1) and showed differential specificity toward other receptor tyrosine kinases. Crystal structures of the tyrosine kinase domain of FGFR1 in complex with the two compounds were determined. The oxindole occupies the site in which the adenine of adenosine triphosphate binds, whereas the moieties that extend from the oxindole contact residues in the hinge region between the two kinase lobes. The more specific inhibitor of FGFR1 induces a conformational change in the nucleotide-binding loop. This structural information will facilitate the design of new inhibitors for use in the treatment of cancer and other diseases in which cell signaling by tyrosine kinases plays a crucial role in disease pathogenesis.

Bibliography

Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R., & Schlessinger, J. (1997). Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors. Science, 276(5314), 955–960.

Authors 8
  1. Moosa Mohammadi (first)
  2. Gerald McMahon (additional)
  3. Li Sun (additional)
  4. Cho Tang (additional)
  5. Peter Hirth (additional)
  6. Brian K. Yeh (additional)
  7. Stevan R. Hubbard (additional)
  8. Joseph Schlessinger (additional)
References 61 Referenced 964
  1. Bishop J. M., Science 235, 305 (1987); (10.1126/science.3541204) / Science by Bishop J. M. (1987)
  2. Ullrich A., Schlessinger J., Cell 61, 203 (1990) ; (10.1016/0092-8674(90)90801-K) / Cell by Ullrich A. (1990)
  3. 10.1126/science.1659742
  4. 10.1126/science.7892601
  5. Basilico C., Moscatelli D., Adv. Cancer Res. 59, 115 (1992). (10.1016/S0065-230X(08)60305-X) / Adv. Cancer Res. by Basilico C. (1992)
  6. Jaye M., Schlessinger J., Dionne C., Biochim. Biophys. Acta 1135, 185 (1992). (10.1016/0167-4889(92)90136-Y) / Biochim. Biophys. Acta by Jaye M. (1992)
  7. Reardon W., et al., Nature Genet. 8, 98 (1994); (10.1038/ng0994-98) / Nature Genet. by Reardon W. (1994)
  8. Neilson K. M., Friesel R. E., J. Biol. Chem. 270, 26037 (1995). (10.1074/jbc.270.44.26037) / J. Biol. Chem. by Neilson K. M. (1995)
  9. Shiang R., et al., Cell 78, 335 (1994); (10.1016/0092-8674(94)90302-6) / Cell by Shiang R. (1994)
  10. Rousseau F., et al., Nature 371, 252 (1994); (10.1038/371252a0) / Nature by Rousseau F. (1994)
  11. Webster M. K., Donoghue D. J., EMBO J. 15, 520 (1996). (10.1002/j.1460-2075.1996.tb00384.x) / EMBO J. by Webster M. K. (1996)
  12. Naski M. C., et al., Nature Genet. 13, 233 (1996). (10.1038/ng0696-233) / Nature Genet. by Naski M. C. (1996)
  13. Tavormina P. L., et al., ibid. 9, 321 (1995); / ibid. by Tavormina P. L. (1995)
  14. Webster M. K., et al., Mol. Cell. Biol. 16, 4081 (1996). (10.1128/MCB.16.8.4081) / Mol. Cell. Biol. by Webster M. K. (1996)
  15. Klagsbrun M., Edelman E. R., Arteriosclerosis 9, 269 (1989); (10.1161/01.ATV.9.3.269) / Arteriosclerosis by Klagsbrun M. (1989)
  16. ; H. Brem and M. Klagsbrun in Oncogenes and Tumor Suppressor Genes in Human Malignancies C. C. Benz and E. T. Liu Eds. (Kluwer Academic Boston 1993) p. 211; M. Klagsbrunand P. A. D’Amore Ann. Rev. Physiol. 53 217 (1991). (10.1007/978-1-4615-3088-6_10)
  17. Adnane J., et al., Oncogene 6, 659 (1991); / Oncogene by Adnane J. (1991)
  18. Penault-Llorca F., et al., Int. J. Cancer 61, 170 (1995); (10.1002/ijc.2910610205) / Int. J. Cancer by Penault-Llorca F. (1995)
  19. Jacquemier J., et al., ibid. 59, 373 (1994); / ibid. by Jacquemier J. (1994)
  20. McLeskey S. W., Ding I. Y., Lippman M. E., Kern F. G., Cancer Res. 54, 523 (1994); / Cancer Res. by McLeskey S. W. (1994)
  21. Luqmani Y. A., et al., Int. J. Cancer 64, 274 (1995); (10.1002/ijc.2910640411) / Int. J. Cancer by Luqmani Y. A. (1995)
  22. Jaakkola S., et al., ibid. 54, 374 (1993). / ibid. by Jaakkola S. (1993)
  23. Leung H. Y., Gullick W. J., Lemoine N. R., Int. J. Cancer 59, 667 (1994). (10.1002/ijc.2910590515) / Int. J. Cancer by Leung H. Y. (1994)
  24. F. Yamaguchi H. Saya J. M. Bruner R. S. Morrison Proc. Natl. Acad. Sci. U.S.A. 91 484 (1994); (10.1073/pnas.91.2.484)
  25. Morrison R. S., et al., J. Neurooncol. 18, 207 (1994). (10.1007/BF01328955) / J. Neurooncol. by Morrison R. S. (1994)
  26. Myoken Y., et al., Int. J. Cancer 65, 650 (1996). (10.1002/(SICI)1097-0215(19960301)65:5<650::AID-IJC15>3.0.CO;2-B) / Int. J. Cancer by Myoken Y. (1996)
  27. Li J. J., et al., Cancer 72, 2253 (1993). (10.1002/1097-0142(19931001)72:7<2253::AID-CNCR2820720732>3.0.CO;2-4) / Cancer by Li J. J. (1993)
  28. Theillet C., et al., Genes Chromosomes Cancer 7, 219 (1993). (10.1002/gcc.2870070407) / Genes Chromosomes Cancer by Theillet C. (1993)
  29. Story M. T., World J. Urol. 13, 297 (1995); (10.1007/BF00185973) / World J. Urol. by Story M. T. (1995)
  30. Ware J. L., Cancer Metastasis Rev. 12, 287 (1993). (10.1007/BF00665959) / Cancer Metastasis Rev. by Ware J. L. (1993)
  31. Preparation of 3-[4-(1-formylpiperazin-4-yl)benzylidenyl]-2-indolinone (SU4984) was as follows: A reaction mixture of 133.15 mg (1.0 mmol) of oxindole 228.3 mg (1.2 mmol) of 4-(1-formylpiperazin-4- yl)benzaldehyde and three drops of piperidine in 2 ml of ethanol was stirred at 90°C for 5 hours. After cooling the precipitate was filtered washed with cold ethanol and dried to yield 199.5 mg (65%) of SU4984 as a yellow solid. Nuclear magnetic resonance (NMR) spectroscopy showed that SU4984 exists predominantly in the trans configuration (C-2 C-1′) although in the crystal structure SU4984 is observed in the cis configuration. Preparation of 3-[(3-(2-carboxyethyl)-4-methylpyrrol-2-yl)methylene]-2-indolinone (SU5402) was as follows: A reaction mixture of 134.0 mg (1.0 mmol) of oxindole 217.43 mg (1.2 mmol) of 3-(2-carboxyethyl)-4-methylpyrrol-2-carboxaldehyde and three drops of piperidine in 3 ml of ethanol was stirred at 90°C for 3 hours. After cooling the precipitate was filtered washed with cold ethanol and dried to yield 172.4 mg (58%) of SU5402 as a yellow solid. NMR spectroscopy showed that SU5402 exists predominantly in the cis configuration.
  32. The compounds were dissolved in dimethylsulfoxide (DMSO) as 100 mM stock solutions and stored at 4°C. The compounds were then diluted in DMSO to a concentration 20× the final concentration used in the in vitro kinase reactions. FGFR1K (9 μl) [2.2 mg/ml in 10 mM tris (pH 8) and 10 mM NaCl] was mixed with 1 μl of various concentrations of 20× SU4984 or 20× SU5402 or with 1 μl of DMSO (control). The reaction was started by adding 6 μl of the enzyme-compound mixture to 6 μl of 2× kinase buffer {2 mM ATP/[γ- 32 P]ATP (10 μCi/μl) 4 mM MgCl 2 in 10 mM tris (pH 8) and 10 mM NaCl} at room temperature. At various time points 2 μl of the reaction mixture was removed and added to 4 μl of 20 mM EDTA to stop the reaction. The reaction products were analyzed by SDS-PAGE (12% gel) and autoradiography. The radioactive bands were excised from the gel and 32 P incorporation was quantitated by Cerenkov counting with a β counter.
  33. NIH 3T3 cells expressing endogenous FGF receptors were used. Cell culture cell lysis immunoprecipitation and immunoblotting were carried out according to standard procedures. Anti-FGFR1 was described previously [
  34. Mohammadi M., et al., Mol. Cell. Biol. 16, 977 (1996)]. (10.1128/MCB.16.3.977) / Mol. Cell. Biol. by Mohammadi M. (1996)
  35. [ 3 H]Thymidine incorporation was done as described by Mohammadi et al. (19).
  36. NIH 3T3 cells expressing endogenous PDGF receptors were used. Also used were HER14 cells (33) and NIHIR cells [
  37. Isakoff S. J., et al., J. Biol. Chem. 271, 3959 (1996); (10.1074/jbc.271.8.3959) / J. Biol. Chem. by Isakoff S. J. (1996)
  38. ]. The EGF receptor was immunoprecipitated with monoclonal antibody 108 (33) insulin receptor with monoclonal antibodies (BBE) [
  39. Moller N. P., et al., J. Biol. Chem. 270, 23126 (1995); (10.1074/jbc.270.39.23126) / J. Biol. Chem. by Moller N. P. (1995)
  40. ] and PDGF receptor with polyclonal antibodies (PR4) [
  41. Mori S., et al., EMBO J. 12, 2257 (1993)]. (10.1002/j.1460-2075.1993.tb05879.x) / EMBO J. by Mori S. (1993)
  42. Mohammadi M., Schlessinger J., Hubbard S. R., Cell 86, 577 (1996). (10.1016/S0092-8674(00)80131-2) / Cell by Mohammadi M. (1996)
  43. 10.1016/S0969-2126(00)00036-8
  44. Thomas K. A., Smith G. M., Thomas T. B., Feldman R. J., Proc. Natl. Acad. Sci. U.S.A. 79, 4843 (1982). (10.1073/pnas.79.16.4843) / Proc. Natl. Acad. Sci. U.S.A. by Thomas K. A. (1982)
  45. G. McMahon unpublished results.
  46. S. R. Hubbard in preparation.
  47. ___, Wei L., Ellis L., Hendrickson W. A., Nature 372, 746 (1994). (10.1038/372746a0) / Nature by ___ (1994)
  48. Lyall R. M., et al., J. Biol. Chem. 264, 14503 (1989); (10.1016/S0021-9258(18)71707-9) / J. Biol. Chem. by Lyall R. M. (1989)
  49. Margolis B., et al., Cell 57, 1101 (1989). (10.1016/0092-8674(89)90047-0) / Cell by Margolis B. (1989)
  50. De Azevedo W. F., et al., Proc. Natl. Acad. Sci. U.S.A. 93, 2735 (1996); (10.1073/pnas.93.7.2735) / Proc. Natl. Acad. Sci. U.S.A. by De Azevedo W. F. (1996)
  51. Schulze-Gahmen U., et al., Proteins Struct. Funct. Genet. 22, 378 (1995). (10.1002/prot.340220408) / Proteins Struct. Funct. Genet. by Schulze-Gahmen U. (1995)
  52. Xu R.-M., Carmel G., Kuret J., Cheng X., Proc. Natl. Acad. Sci. U.S.A. 93, 6308 (1996). (10.1073/pnas.93.13.6308) / Proc. Natl. Acad. Sci. U.S.A. by Xu R.-M. (1996)
  53. Engh R. A., Girod A., Kinzel V., Huber R., Bossemeyer D., J. Biol. Chem. 271, 26157 (1996). (10.1074/jbc.271.42.26157) / J. Biol. Chem. by Engh R. A. (1996)
  54. M. G. Malkin W. P. Mason F. S. Lieberman L. K. Shawver A. L. Hannah in Proceedings of the 32nd Annual Meeting of the American Society of Clinical Oncology Philadelphia PA 18 to 21 May 1996 (American Society of Clinical Oncology Philadelphia PA 1996) vol. 15 p. 1573.
  55. Honegger A. M., et al., Cell 51, 199 (1987). (10.1016/0092-8674(87)90147-4) / Cell by Honegger A. M. (1987)
  56. 10.1016/0263-7855(93)87009-T
  57. 10.1002/prot.340110407
  58. Z. Otwinowski in Data Collection and Processing L. Sawyer N. Isaacs S. Bailey Eds. (SERC Daresbury Laboratory Warrington UK 1993) p. 56.
  59. A. T. Brünger X-PLOR Version 3.1: A System for X-ray and NMR (Yale Univ. Press New Haven CT 1992).
  60. Jones T. A., Methods Enzymol. 115, 157 (1985). (10.1016/0076-6879(85)15014-7) / Methods Enzymol. by Jones T. A. (1985)
  61. Equipment in the structural biology program at the Skirball Institute is partially supported by a grant from the Kresge Foundation. Coordinates have been deposited in the Brookhaven Protein Data Bank entries 1FGI and 1AGW.
Dates
Type When
Created 23 years, 1 month ago (July 27, 2002, 1:45 a.m.)
Deposited 1 year, 7 months ago (Jan. 12, 2024, 7:46 p.m.)
Indexed 1 day, 12 hours ago (Aug. 26, 2025, 2:30 a.m.)
Issued 28 years, 3 months ago (May 9, 1997)
Published 28 years, 3 months ago (May 9, 1997)
Published Print 28 years, 3 months ago (May 9, 1997)
Funders 0

None

@article{Mohammadi_1997, title={Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors}, volume={276}, ISSN={1095-9203}, url={http://dx.doi.org/10.1126/science.276.5314.955}, DOI={10.1126/science.276.5314.955}, number={5314}, journal={Science}, publisher={American Association for the Advancement of Science (AAAS)}, author={Mohammadi, Moosa and McMahon, Gerald and Sun, Li and Tang, Cho and Hirth, Peter and Yeh, Brian K. and Hubbard, Stevan R. and Schlessinger, Joseph}, year={1997}, month=may, pages={955–960} }